 | • レポートコード：D0-MOR-AP0874 • 出版社/出版日：Mordor Intelligence / 2020年4月20日 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：健康管理 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、腫瘍In-Vivo CROの世界市場について調査・分析した資料で、腫瘍In-Vivo CROの市場概要、動向、セグメント別市場規模、地域別分析、競争状況、企業情報、市場機会分析などで構成されています。 |
The Oncology Based In-Vivo CRO market studied is anticipated to grow with a CAGR of 7.3%, during the forecast period. The major factors attributing to the growth of the oncology based In-Vivo CRO market are the rising incidence of cancer cases worldwide. A rise in the geriatric population is also propelling the growth for the oncology based In-Vivo CRO market. Owing to the increasing number of specific therapies in the oncology pipeline and the presence of large number of pipeline drugs, the number of late-stage pipeline therapies rose from 711 in 2017 to 849 in 2018 – an increase of 19% and the use of oncology based In-Vivo CRO help in deriving the novel therapies for the diagnosis, prevention, and treatment to patients which is further expected to boost the market growth. In addition to the development of vaccines for infectious diseases, oncology is among the most studied indication, as per the statistics available from government agencies around the world. And there are few more factors that are playing crucial roles in taking the oncology based In-Vivo CRO market to the next level, among them federal funding for research studies and increasing treatment for cancer and research expertise, which are expected to propel the growth of oncology based In-Vivo CRO market. As per the North American Association of Central Cancer Registries (NAACCR) 2019 data, there will be an estimated 176,2450 new cancer cases in the U.S.
Key Market Trends
Solid Tumor Segment is Expected to Hold the Largest Market Share in the Oncology Based In-Vivo CRO Market
– As per the statistics from GLOBOCAN 2018, there is an estimated 2,129,118 number of incident cases in the United States, in 2018, which is expected to grow by 2040 and reach a number of 3,096,944 cases. Additionally, the pressure through increased competition as a result of patent expirations, the rapid growth of generics and the launch of the biosimilars are prompting pharmaceutical manufacturers to take support from these organizations (CRO) for research and development.
– As per the statistics from GLOBOCAN 2018, worldwide 18,078,957 individuals have cancer. Asia remains the leading contributor in the rising incidence of cancer with a reported share of 48.4% followed by Europe, North and Latin America, Africa, and Oceania with a share of 23.4%, 13.2% and 7.8%, 5.8%, and 1.4% respectively.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the overall oncology based In-Vivo CRO market, throughout the forecast period. This is owing to factors such as the rising prevalence of cancer and the availability of advanced healthcare infrastructure and the presence of a large number of CROs in the region among the major factors. In North America region, the United States holds the largest market share owing to the factors such as increasing number of population suffering from cancer, along with the rising geriatric population and research & developments related to cancer therapy and rising government initiative for the awareness of cancer in the country, is anticipated to further drive the oncology based In-Vivo CRO market in this region.
Competitive Landscape
The oncology based In-Vivo CRO market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. And some prominent players are vigorously making acquisitions and joint ventures with the other companies to consolidate their market positions across the globe. Some of the companies which are currently dominating the market are Crown Bioscience Inc., Charles River Laboratories, Inc., ICON plc, Taconic Biosciences, Inc., and Covance Inc.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising incidence of Cancer Globally
4.3 Market Restraints
4.3.1 High Cost of Cancer Therapies
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Indication
5.1.1 Blood Cancer
5.1.2 Solid Tumors
5.1.3 Other Indications
5.2 By Model
5.2.1 Syngeneic
5.2.2 Xenograft
5.2.3 Patient Derived Xenograft (PDX)
5.2.4 Other Models
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Crown Bioscience Inc.
6.1.2 Charles River Laboratory, Inc.
6.1.3 ICON Plc
6.1.4 Taconic Biosciences, Inc.
6.1.5 Covance Inc.
6.1.6 Eurofins Scientific
6.1.7 EVOTEC
6.1.8 The Jackson Laboratory
6.1.9 Wuxi AppTec.
6.1.10 MI Bioresearch, Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS